Regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere.
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
Elobixibat, is a novelly formulated chronic-constipation treatment that modulates the flow of bile to motivate bowel movements.
Astellas Pharma extended its deal with Pfizer ($PFE) to market the cholesterol drug Lipitor in Japan.
After announcing the tie-up almost a year ago, India's Dr. Reddy's Laboratories ($RDY) finally expects to ink a joint venture agreement with Fujifilm.
Here's another hint of Japan's new openness to Big Pharma: a proposed compassionate use program. The government is considering allowing drugs for serious diseases to be sold in Japan while they're still in clinical trials there, so long as they're approved in foreign markets such as the U.S. or Europe
GlaxoSmithKline ($GSK) and Daiichi Sankyo have signed a joint venture agreement to create what GSK believes will be the largest vaccines company in Japan.
GlaxoSmithKline ($GSK) and Japan's number three pharma company Daiichi Sankyo have created a joint venture to bring new treatments to the Japanese market.
Just last week, GlaxoSmithKline ($GSK) CEO Andrew Witty (photo) slighted European markets by touting Japan as a superior place to sell drugs these days. Japan's moves to speed new drugs to market...
Europe is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to